<DOC>
	<DOC>NCT02539953</DOC>
	<brief_summary>One in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. The investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic effect.</brief_summary>
	<brief_title>Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Aged 1875 years Able to provide written, informed consent Taking rivaroxaban for any indication within the license of the drug, both once daily and twice daily dosing can be included Have measurable rivaroxaban levels on at least one occasion (this will be in line with standard of care, there will be no extra blood samples for the study) Not taking concomitant medication that can affect rivaroxaban metabolism (including amiodarone, dronedarone, azole antifungals, protease inhibitors) On no antihypertensive or vasoactive medication Have a baseline BP recording taken in clinic Unable to provide written, informed consent Presence of concomitant medication that may alter rivaroxaban levels and confound results (see above) Unwilling to undergo ambulatory blood pressure monitoring Contraindication to ambulatory blood pressure monitoring</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>